Cipla gains despite its arm receives two inspectional observations from USFDA
InvaGen has received two inspectional observations for its manufacturing facility located in Long Island
Cipla is currently trading at Rs. 1347.65, up by 5.55 points or 0.41% from its previous closing of Rs. 1342.10 on the BSE.
The scrip opened at Rs. 1348.20 and has touched a high and low of Rs. 1350.00 and Rs. 1335.00 respectively. So far 29185 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1672.20 on 23-Oct-2025 and a 52 week low of Rs. 1283.00 on 27-Jan-2026.
Last one week high and low of the scrip stood at Rs. 1358.35 and Rs. 1316.90 respectively. The current market cap of the company is Rs. 108925.19 crore.
The promoters holding in the company stood at 29.21%, while Institutions and Non-Institutions held 54.64% and 16.14% respectively.
Cipla’s wholly owned subsidiary -- InvaGen Pharmaceuticals, Inc. (InvaGen) has received two inspectional observations in Form 483 from United States Food and Drug Administration (USFDA) for its manufacturing facility located in Long Island, New York, USA.
The USFDA had conducted a Pre-Approval Inspection (PAI) at the said manufacturing facility from February 2, 2026 to February 9, 2026.
Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).
